Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Adjuvant IL-12 immuno-gene therapy prior to radical prostatectomy in patients with prostate cancer

Proposed period of release:
01/07/2006 to 01/07/2008

Name of the Institute(s) or Company(ies)
Erasmus MC, University Medical Center Rotterdam, ;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Mastadenovirus (genus), human adenovirus (species). The GMO is a replication incompetent recombinant adenovirus (human serotype 5) containing the human gene for interleukin-12 (referred to as Adv/IL-12)

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
human serotype 5 (Ad5)Mastadenovirushuman adenovirussubgroup Chuman serotype 5 (Ad5)

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known